Does dual antiplatelet therapy (clopidogrel-aspirin) improve outcomes in patients with minor ischemic stroke or high-risk TIA?
The clinical benefit of dual antiplatelet therapy with clopidogrel and aspirin is concentrated in the first 21 days following a minor ischemic stroke or high-risk TIA.
In this analysis of the POINT and CHANCE trials, the benefit of dual antiplatelet therapy appeared to be confined to the first 21 days after minor ischemic stroke or high-risk TIA.
Pan et al. (Mon,) studied this question.